{
    "address": "Lunastigen 7",
    "city": "Huddinge",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W56151108",
    "description": "Medivir AB engages in the development of pharmaceuticals products. The company is headquartered in Huddinge, Stockholm and currently employs 9 full-time employees.  The firm specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The firm's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.",
    "employeeTotal": "9.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "1996-02-29",
    "isin": "SE0000273294",
    "logo": "https://finnhub.io/api/logo?symbol=MVIR B.ST",
    "marketCapitalization": 468.1795,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Medivir AB",
    "phone": "46854683100.0",
    "sedol": "5096800",
    "shareOutstanding": 55.736,
    "state": "STOCKHOLM",
    "ticker": "MVIR B.ST",
    "weburl": "https://www.medivir.se/"
}